Medical Breakthrough, Bureaucratic Breakdown - Carl June, MD, discusses translational medicine and its bureaucratic obstacles

June 9, 2010


Carl June, MD, director of translational research at the Abramson Family Cancer Research Institute, talks on NPR affiliate KPCC-FM (Los Angeles) about translational medicine and the bureaucratic obstacles in getting more breakthroughs to patients: "It's very, very complex... In academia, in general, people are promoted based on short-term projects, so it's hard for them to gauge a long-term project, which may be risky, and then the academic ladder isn't climbed. The average drug development time from when you first start a human trial to getting FDA approval is about 12 years and the longest NIH grant is five year." Read More